Видео ютуба по тегу Destin Cancer

ESMO25 Breast Cancer Highlights: DESTINY-Breast11 & DESTINY-Breast05 | Dana-Farber Cancer Institute
ESMO25 Breast Cancer Highlights: DESTINY-Breast11 & DESTINY-Breast05 | Dana-Farber Cancer Institute
DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markers
DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markers
DESTINY-Gastric05: first-line T-DXd ± pembrolizumab in HER2+ gastric cancer
DESTINY-Gastric05: first-line T-DXd ± pembrolizumab in HER2+ gastric cancer
ADC при метастатическом раке молочной железы на ранних стадиях: данные DESTINY-Breast09 и ASCENT-03
ADC при метастатическом раке молочной железы на ранних стадиях: данные DESTINY-Breast09 и ASCENT-03
ASCO 2025 - Breast Cancer Highlights: INAVO120, SERENA-6, VERITAC-2, DESTINY-Breast09, ASCENT-04
ASCO 2025 - Breast Cancer Highlights: INAVO120, SERENA-6, VERITAC-2, DESTINY-Breast09, ASCENT-04
DESTINY-Breast04: practice-changing results for HER2-low breast cancer
DESTINY-Breast04: practice-changing results for HER2-low breast cancer
DESTINY-CRC02: antibody-drug conjugates in colorectal cancer
DESTINY-CRC02: antibody-drug conjugates in colorectal cancer
DESTINY-Breast12: T-DXd in patients with HER2+/HR- breast cancer with brain metastasis
DESTINY-Breast12: T-DXd in patients with HER2+/HR- breast cancer with brain metastasis
T-DXd против T-DM1 при HER2+ раке молочной железы высокого риска: промежуточные данные DESTINY-Br...
T-DXd против T-DM1 при HER2+ раке молочной железы высокого риска: промежуточные данные DESTINY-Br...
Ключевые достижения в области HER2-позитивного рака молочной железы к 2025 году: исследования DES...
Ключевые достижения в области HER2-позитивного рака молочной железы к 2025 году: исследования DES...
Biomarker-based personalization for HER2-low breast cancer treatment in DESTINY-Breast04
Biomarker-based personalization for HER2-low breast cancer treatment in DESTINY-Breast04
Рак молочной железы с низким уровнем HER2: СУДЬБА или здравый смысл?
Рак молочной железы с низким уровнем HER2: СУДЬБА или здравый смысл?
ASCO25: Sara Tolaney, MD, MPH DESTINY-Breast09 | Dana-Farber Cancer Institute
ASCO25: Sara Tolaney, MD, MPH DESTINY-Breast09 | Dana-Farber Cancer Institute
Breast Cancer ESMO 2025 Highlights: MonarchE, NATALEE, VIKTORIA1, evERA, DESTINY, ASCENT, TROPION
Breast Cancer ESMO 2025 Highlights: MonarchE, NATALEE, VIKTORIA1, evERA, DESTINY, ASCENT, TROPION
ASCO 2025 - GI Cancer Highlights: DYNAMIC III, ATOMIC, BREAKWATER, MATTERHORN, DESTINY Gastric04
ASCO 2025 - GI Cancer Highlights: DYNAMIC III, ATOMIC, BREAKWATER, MATTERHORN, DESTINY Gastric04
Making Strides for Breast Cancer Awareness hosts drive-thru event at Destiny U.S.A.
Making Strides for Breast Cancer Awareness hosts drive-thru event at Destiny U.S.A.
Dr. Dang on the DESTINY-Breast01 Trial in HER2+ Metastatic Breast Cancer
Dr. Dang on the DESTINY-Breast01 Trial in HER2+ Metastatic Breast Cancer
Breast cancer updates at ASCO 2025: SERENA-6, DESTINY-Breast09 & ASCENT-04
Breast cancer updates at ASCO 2025: SERENA-6, DESTINY-Breast09 & ASCENT-04
DESTINY-Breast04 Study: T-DXd Breakthrough for HER2-Low Breast Cancer Treatment
DESTINY-Breast04 Study: T-DXd Breakthrough for HER2-Low Breast Cancer Treatment
Why Destiny Was So Confident on Calling Out Boogie Faking Cancer
Why Destiny Was So Confident on Calling Out Boogie Faking Cancer